Xenon Pharmaceuticals Inc.
XENE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001582313
In the last 90 days, Xenon Pharmaceuticals Inc. insiders filed 2 open-market purchases and 2 sales; 315 institutions reported holding it in 13F filings for Q2 2026, worth $6.10B in total; Duquesne Family Office is the only superinvestor holding it.
Q3 2024 vs. Q2 2024
How the institutions holding Xenon Pharmaceuticals Inc. changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 213 | 1 | 203 | −9 |
| Shares | 74.2M | 2.10M | 74.9M | +2.82M (+3.9%) |
| Value | $2.89B | $81.7M | $2.95B | +$139.5M (+5.0%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (15)
Institutions that held Xenon Pharmaceuticals Inc. at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 2,105,562 | $82.9M | 0.00% |
| Siren, L.L.C. | 743,769 | $29.3M | 1.47% |
| MPM Oncology Impact Management LP | 165,800 | $6.53M | 0.98% |
| Walleye Capital LLC | 104,960 | $4.13M | 0.04% |
| Ameriprise Financial Inc | 66,383 | $2.61M | 0.00% |
| Nicholas Investment Partners, LP | 14,658 | $577.1K | 0.05% |
| Brevan Howard Capital Management LP | 12,012 | $472.9K | 0.02% |
| Occudo Quantitative Strategies LP | 10,811 | $425.6K | 0.08% |
| Vestcor Inc | 8,300 | $327.0K | 0.01% |
| Squarepoint Ops LLC | 7,504 | $295.4K | 0.00% |
| nVerses Capital, LLC | 2,600 | $102.4K | 0.05% |
| Clear Street Markets LLC | 90 | $4.00K | 0.00% |
| Danske Bank A/S | 100 | $3.94K | 0.00% |
| Wolff Wiese Magana LLC | 61 | $2.40K | 0.00% |
| J.Safra Asset Management Corp | 11 | $425 | 0.00% |
Sold out (24)
Institutions that held Xenon Pharmaceuticals Inc. at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Paradigm Biocapital Advisors LP | 2,043,280 | $79.7M |
| Artal Group S.A. | 381,554 | $14.9M |
| Logos Global Management LP | 375,000 | $14.6M |
| Boone Capital Management LLC | 250,460 | $9.77M |
| Laurion Capital Management LP | 171,195 | $6.67M |
| Tri Locum Partners LP | 101,959 | $3.98M |
| Twinbeech Capital LP | 88,711 | $3.46M |
| CenterBook Partners LP | 29,153 | $1.14M |
| Susquehanna International Group, LLP | 23,036 | $898.2K |
| Eisler Capital (US) LLC | 22,018 | $858.5K |
| Cinctive Capital Management LP | 20,520 | $800.1K |
| Jane Street Group, LLC | 14,755 | $575.3K |
| XTX Topco Ltd | 11,910 | $464.4K |
| SEI Investments Co | 7,909 | $308.4K |
| Vident Advisory, LLC | 7,082 | $276.1K |
| American Century Companies Inc | 5,979 | $233.1K |
| Snowden Capital Advisors LLC | 5,511 | $214.9K |
| Aquatic Capital Management LLC | 4,200 | $163.8K |
| Quarry LP | 4,000 | $156.0K |
| Simplex Trading, LLC | 2,589 | $100.0K |
| Allianz SE | 1,200 | $46.8K |
| Ashton Thomas Private Wealth, LLC | 135 | $5.26K |
| Massmutual Trust Co FSB | 40 | $1.56K |
| EntryPoint Capital, LLC | 26 | $1.01K |
Not filed for Q3 2024 yet (1)
Institutions that held Xenon Pharmaceuticals Inc. at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 2,095,894 | $81.7M |